



Rx WIRE

A weekly service from
Pharmaceutical Strategies Group.

February 3, 2017

Creating opportunity for our clients with an exclusive focus on pharmacy solutions.

Pharmaceutical Strategies Group Unveils 340B Product Rebranding

Business Wire - February 1




Pharmaceutical Strategies Group, an integrated technology-enabled pharmacy solutions and cost-containment company, has rebranded its 340B solutions and will be unveiling PSG 340B Link™ at the 340B Coalition Winter Conference being held in San Francisco, CA, from February 1-3.

[READ MORE](#)

Does Pharma Really Want to Overhaul FDA?

Pharma Exec - February 1



In a much-publicized White House meeting this week with top biopharma executives, president Donald Trump promised to "streamline" FDA operations to speed up approval decisions on new drugs and medical products.

[READ MORE](#)

SUMMARY OF TOP ARTICLES

How to Rein In the Soaring Costs of Specialty Drugs

CFO - January 30

The National Business Group on Health (NBGH), a nonprofit association of 420 large U.S. employers, on Monday released a policy issue brief offering recommendations designed to help stem the skyrocketing costs of "specialty" drugs.

Seven Questions To Ask About Republican Health Plans

Forbes - January 31

Republican proposals to replace Obamacare seem to be emerging at a dizzying pace. To help sort through them, my brother Jeff Goodman has prepared the chart below.

Health insurers warn of wider defections from ACA marketplaces for 2018

Washington Post - February 1

Leaders for the health insurance industry, state insurance commissioners and brokers warned Wednesday that more health plans almost certainly will defect from Affordable Care Act marketplaces unless Congress and the Trump administration provide some concrete assurances within the next two months.

U.S. House panel to take up bill to spur generic drug development

Reuters - February 2

A U.S. House of Representatives subcommittee will take up bipartisan legislation next week to foster generic drug development, the committee's chairman, Representative Greg Walden, said on Thursday.

Senator, NABP Call for Better Detection of Drug Interaction After Chicago Investigation

Drug Topics - January 30

The National Association of Boards of Pharmacy and U.S. Senator Dick Durbin (D-IL) are calling for new pharmacy safety policies after a Chicago Tribune investigation found that pharmacists at several drug store chains filled scripts with dangerous drug combinations.

Diabetes Patients Hit Back: File Suit Against Insulin Companies

Medscape - February 1

A group of diabetes patients have filed a class-action lawsuit in the United States against three insulin manufacturers, Eli Lilly, Novo Nordisk, and Sanofi, alleging that they conspired in an organized scheme to drive up prices.

Women Fear Drug They Used To Halt Puberty Led To Health Problems

Kaiser Health News - February 2

For years, Sharissa Derricott, 30, had no idea why her body seemed to be failing. At 21, a surgeon replaced her deteriorated jaw joint.

Walgreens Slashes Offer for Rite Aid, Pushes Back Deadline

Drug Discovery & Development - February 2

Walgreens substantially lowered its offering price for drugstore rival Rite Aid and, facing resistance from U.S. regulators, raised the number of stores it would be willing to unload to ease monopoly concerns.

Medicare Part D rebates leap as PBMs drive hard bargains, but patients don't benefit

FiercePharma - January 30

As the drug industry braces for fresh pricing action as vowed by President Donald Trump, a report by the Centers for Medicare and Medicaid Services documents a "significant" increase in rebates in Part D prescription plans.

Old drug gets new trick for prostate cancer treatment

STAT - February 1

A commonly used drug could dramatically increase survival rates for men who have to fight prostate cancer twice.

Novartis says court battle will delay its Enbrel copy until 2018 at least

Reuters - January 25

The Novartis copy of Amgen's blockbuster psoriasis drug Enbrel will not go on sale before 2018 at the earliest because of the U.S. company's patent protection challenge, the Swiss drugmaker's head of generics told Reuters.

FDA NEWS

FDA Lashes Out at Jazz Pharma (JAZZ) CMO for Continued Regulatory Violations

BioSpace - January 27

The U.S. Food and Drug Administration issued a warning letter to U.K.-based Porton Biopharma for continued regulatory violations in the manufacturing process, particularly a leukemia drug made for Jazz Pharmaceuticals (JAZZ).

NARCAN[®] (naloxone HCl) Nasal Spray 2mg Approved by U.S. Food and Drug Administration (FDA)

Adapt Pharma - January 25

Today, the U.S. Food and Drug Administration (FDA) approved NARCAN[®] Nasal Spray as a 2mg formulation for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

Aurobindo earns FDA approval for multiple sclerosis generic

Drug Store News - January 26

The U.S. Food and Drug Administration approved Aurobindo Pharma's Dalfampridine Extended-Release tablets, 10 mg, intended for treatment of multiple sclerosis.

FDA approves OTC Xyzal to treat allergies

Healio - February 1

Today, Sanofi announced that Xyzal Allergy 24HR has been approved by the FDA for over-the-counter use to relieve seasonal and year-round allergy symptoms, according to a press release.



Copyright © 2017 Pharmaceutical Strategies Group LLC. All rights reserved.
www.psgconsults.com | 800.687.4404
2901 N. Dallas Pkwy. Suite #420 | Plano, TX 75093

ABOUT YOUR SUBSCRIPTION

You have received this email because you are signed up to receive RxWire from Pharmaceutical Strategies Group LLC. If you would like to stop receiving the RxWire newsletter, please [manage your preferences](#). If you know someone who would be excited to hear from us as well, forward this email to your friend. If your email address has changed, please [update your account](#). Your privacy is our responsibility, and know that we do not rent, share or sell your email address or contact information with anyone. This email was sent to ckosha@nnebt.org.

Window size: x
Viewport size: x